Navigation Links
MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,,Australia

"Electroloading of mature dendritic cells with tumor lysate triggers robust antigen-specific CTL response"

GAITHERSBURG, Md., and YOKOHAMA, Japan, June 22, 2007 /PRNewswire/ -- MaxCyte, Inc. and Medinet Co., Ltd. announce a joint poster presentation at the 13th Annual Meeting of the International Society for Cellular Therapy. The meeting is being held June 24-27, 2007 in Sydney, Australia.

The presentation is entitled "Electroloading of mature dendritic cells with tumor lysate triggers robust antigen-specific CTL response" and will discuss the findings of a study that combined MaxCyte's technologies and Medinet's novel immuno-cell therapy technologies to produce more potent cancer vaccines. The session is scheduled for Monday, June 25 from 6:30-10:30 p.m.

The study was performed under a collaboration agreement in which MaxCyte optimized its proprietary cell loading technology for the development of Medinet's novel cancer immuno-cell therapy service for implementation in a closed-system, cGMP manufacturing process at Medinet's cell processing centers in Japan.

The presentation will discuss the development of a robust, scalable, cGMP compliant manufacturing process and the resulting production of dendritic cell (DC) vaccines with enhanced potency as demonstrated by higher antigen-specific T cell stimulation compared to current manufacturing processes. Final immunotherapeutic product exhibited high (>95%) cell viability and purity and showed characteristic DC immunophenotype as detected by increased expression of HLA class I, HLA class II, and co-stimulatory molecules. Compared with current manufacturing processes, this engineered DC product required less antigen but achieved substantially higher antigen loading per cell. The engineered DC vaccine elicited increased frequency of antigenpeptide-specific T cells in a 7 day in vitro stimulated culture, in direct head-to-head comparison with curre nt manufacturing processes. The developed manufacturing methodology uses MaxCyte's proprietary platform technologies that have been described in a Master File with CBER, United States FDA and been cross- referenced in multiple clinical studies, and Medinet's technology and know-how derived from its world-leading experience in autologous cell processing resulting from marketed therapies that have been administered to over 6,000 cancer patients at Medinet's network of Contracted Medical Institutions since 1999.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

For more information, visit http://www.maxcyte.com.

About Medinet

Medinet is a world leading company in cell therapy supporting medical service providers in Japan. Through its service, Medinet provides medical institutions with advanced technologies and knowhow in: cell processing and culturing, qu ality control, and facility management with respect to the immuno-cell therapy. Medinet has extensive experience in autologous cell processing that corresponds to treatment for over 6,000 cancer patients in actual clinical practice. Medinet continues to invest in R&D to improve cell processing technologies in an effort to increase efficacy in collaborative clinical studies with university hospitals and medical institutions. Medinet went public in October 2003 on the MOTHERS, Tokyo Stock Exchange.

For more information, visit http://www.medinet-inc.co.jp/english/.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

CONTACT: Anthony Recupero, Ph.D., Vice President Business Development, ofMaxCyte, Inc., +1-301-944-1700; or Kunihiko Suzuki, General Manager,Corporate Strategy & Planning Department, of Medinet Co., Ltd.,+81(45)478-0046

Web site: http://www.maxcyte.com/http://www.medinet-inc.co.jp/english/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):